Abstract
Alzheimer’s disease is a neurodegenerative disorder that causes a progressive decline of mental and cognitive processes such as memory, judgment and reasoning. We proposed earlier that a sustained loss of function of Wnt/β- catenin signaling components underlies the onset and progression of the disease. Here, we discuss recent data on the involvement of Wnt/b-catenin signaling on amyloid precursor protein (APP) processing, Aβ peptide neurotoxicity, τ phosphorylation, and modulation of Apolipoprotein E function in the brain. We conclude that several components of the cascade are actively engaged in the events leading to AD neuropathology and propose that compounds that mimic activation of this signaling cascade, such as lithium, should be considered for therapeutic intervention in Alzheimer's patients. In summary, data accumulated during the past decade confirm some important predictions of our hypothesis where components of this signaling cascade are actively engaged in the events leading to AD neuropathology and that compounds that mimic activation of this signaling cascade, such as lithium, should be considered for therapeutic intervention in Alzheimer's patients.
Keywords: Alzheimer's disease, amyloid precursor protein, tau, apolipoprotein E, Wnt/β-catenin signaling, lithium.
CNS & Neurological Disorders - Drug Targets
Title:Wnt/β-Catenin Signaling in Alzheimer's Disease
Volume: 13 Issue: 5
Author(s): Giancarlo V. De Ferrari, Miguel E. Avila, Matias A. Medina, Eduardo Perez-Palma, Bernabe I. Bustos and Marcelo A. Alarcon
Affiliation:
Keywords: Alzheimer's disease, amyloid precursor protein, tau, apolipoprotein E, Wnt/β-catenin signaling, lithium.
Abstract: Alzheimer’s disease is a neurodegenerative disorder that causes a progressive decline of mental and cognitive processes such as memory, judgment and reasoning. We proposed earlier that a sustained loss of function of Wnt/β- catenin signaling components underlies the onset and progression of the disease. Here, we discuss recent data on the involvement of Wnt/b-catenin signaling on amyloid precursor protein (APP) processing, Aβ peptide neurotoxicity, τ phosphorylation, and modulation of Apolipoprotein E function in the brain. We conclude that several components of the cascade are actively engaged in the events leading to AD neuropathology and propose that compounds that mimic activation of this signaling cascade, such as lithium, should be considered for therapeutic intervention in Alzheimer's patients. In summary, data accumulated during the past decade confirm some important predictions of our hypothesis where components of this signaling cascade are actively engaged in the events leading to AD neuropathology and that compounds that mimic activation of this signaling cascade, such as lithium, should be considered for therapeutic intervention in Alzheimer's patients.
Export Options
About this article
Cite this article as:
Ferrari V. De Giancarlo, Avila E. Miguel, Medina A. Matias, Perez-Palma Eduardo, Bustos I. Bernabe and Alarcon A. Marcelo, Wnt/β-Catenin Signaling in Alzheimer's Disease, CNS & Neurological Disorders - Drug Targets 2014; 13 (5) . https://dx.doi.org/10.2174/1871527312666131223113900
DOI https://dx.doi.org/10.2174/1871527312666131223113900 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
Call for Papers in Thematic Issues
Diagnosis and treatment of central nervous system infectious diseases
Infectious diseases of the central nervous system (CNS) can be divided into bacterial, tuberculous, viral, fungal, parasitic infections, etc. Early etiological treatment is often the most crucial means to reduce the mortality rate of patients with central nervous system infections, reduce complications and sequelae, and improve prognosis. The initial clinical ...read more
Trends and perspectives in the rational management of CNS disorders
Central nervous system (CNS) diseases enforce a significant global health burden, driving ongoing efforts to improve our understanding and effectiveness of therapy. This issue investigates current advances in the discipline, focusing on the understanding as well as therapeutic handling of various CNS diseases. The issue covers a variety of diseases, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Special Issue on Programmed Cell Death in Stroke
Current Neuropharmacology Thromboxane A<sub>2</sub> Receptor Polymorphism in Association with Cerebral Infarction and its Regulation on Platelet Function
Current Neurovascular Research 14-3-3 Protein in CSF Reflects SIV-Mediated Pre-Synaptic Damage
Current HIV Research Stem Cell Therapy for Alzheimers Disease
CNS & Neurological Disorders - Drug Targets Underlying Mechanisms and Potential Therapeutic Molecular Targets in Blood-Brain Barrier Disruption after Subarachnoid Hemorrhage
Current Neuropharmacology Adoptive Regulatory T-cell Therapy Attenuates Subarachnoid Hemor-rhage-induced Cerebral Inflammation by Suppressing TLR4/NF-B Signaling Pathway
Current Neurovascular Research Mechanisms of Tumor Cell Necrosis
Current Pharmaceutical Design Nimodipine Reappraised: An Old Drug With a Future
Current Neuropharmacology Sestrins: A New Kid for Stroke Treatment?
Current Drug Delivery Omega-3 Polyunsaturated Fatty Acids in Alzheimers Disease: Key Questions and Partial Answers
Current Alzheimer Research Endothelial Progenitor Cells as a Therapeutic Approach for Intracerebral Hemorrhage
Current Pharmaceutical Design Purines and Pyrimidines: Metabolism, Function and Potential as Therapeutic Options in Neurodegenerative Diseases
Current Protein & Peptide Science Immunotherapy for Targeting Tau Pathology in Alzheimer’s Disease and Tauopathies
Current Alzheimer Research Major Highlights of the CAR-TCR Summit, Boston, 2016
Anti-Cancer Agents in Medicinal Chemistry ISCHEMIRs: Finding a Way Through the Obstructed Cerebral Arteries
Current Drug Targets Necroptosis Signaling Pathways in Stroke: From Mechanisms to Therapies
Current Neuropharmacology Elevated Levels of Bilirubin and Long-Term Exposure Impair Human Brain Microvascular Endothelial Cell Integrity
Current Neurovascular Research Molecular Mechanisms in Aging and Current Strategies to Counteract Sarcopenia
Current Aging Science Rational Design and Development of Colon-Specific Prodrugs
Current Topics in Medicinal Chemistry Combination of Therapeutic Hypothermia and Other Neuroprotective Strategies after An Ischemic Cerebral Insult
Current Neuropharmacology